Impact of genetic patterns on sorafenib efficacy in patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: a multi-center, cohort study.

Signal Transduct Target Ther · 2023 · PMC10499827 · PMID 37704613

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Multivariate COX regression results showed that patients with mutated NPM1 (HR 0.48, 95% CI 0.26–0.89; P = 0.02), DNMT3A (HR 0.36, 95% CI 0.15–0.85; P = 0.02), and triple-mutated (HR 0.32, 95% CI 0.10–0.99; P = 0.049) in the sorafenib group had superior OS than the control group, and those with TET2 (HR 0.52; 95% CI 0.24–1.11; P = 0.09) and IDH1/2 (HR 0.37; 95% CI 0.12–1.15; P = 0.09) in the sorafenib group showed a trend of improved OS.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.